Crossmark

PD-1/PD-L1 immune checkpoint inhibitors in the treatment of unresectable locally advanced or metastatic triple negative breast cancer: a meta-analysis on their efficacy and safety

Crossref DOI link: https://doi.org/10.1186/s12885-024-13105-9

Published Online: 2024-10-31

Update policy: https://doi.org/10.1007/springer_crossmark_policy

Authors

Wang, Zuxiu

You, Peimeng

Yang, Zhanglei

Xiao, Hanxi

Tang, Xinrong

Pan, Yongping

Li, Xuhuan

Gao, Feng
Funding

Funding for this research was provided by:

The Fourth Affiliated Hospital of Nanchang University (SKJP220210373)
License Information

Text and Data Mining valid from 2024-10-31

Version of Record valid from 2024-10-31
More Information

Article History

Received: 5 October 2024

Accepted: 24 October 2024

First Online: 31 October 2024

Declarations

:

: Ethical approval: The study did not involve the personal privacy and personal interests of patients, and the medical records and data included in the study were retrospective research data, which were exempted from medical ethics review after approval by the Ethics Committee of our hospital.Consent to participants: Not applicable.

: Not applicable.

: The authors declare no competing interests.

Document is current

Any future updates will be listed below